Search the Newsreel

Optimum Communications (NYSE:OPTU) Misses Q2 CY2026 Sales Expectations

MAXIMUS ($MMS) Releases Q3 2026 Earnings

Maximus beats Q3 earnings but cuts guidance on contract change

Maximus Inc. reported Q3 adjusted earnings per share of $2.22, surpassing analyst estimates, but revenue of $1.28 billion fell short. The company cut its full-year adjusted EPS guidance due to a temporary contractual modification on a major federal program, despite strong adjusted EBITDA margins …

Maximus: Fiscal Q3 Earnings Snapshot

Maximus Inc. (MMS) reported fiscal third-quarter net income of $103.6 million, or $1.95 per share, exceeding analyst expectations with adjusted earnings of $2.22 per share. However, the company's revenue of $1.28 billion fell short of Street forecasts. Maximus anticipates full-year revenue to be between …

Simulations Plus, Inc. (NASDAQ:SLP) Receives Consensus Recommendation of "Reduce" from Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has received a consensus "Reduce" rating from analysts, with an average 12-month price target of $17.25, below its opening price of $18.32. This comes despite the company exceeding quarterly earnings expectations with an EPS of $0.30 and revenue of $21.89 …

Proximus chooses the Digital Vending Machine® from Bango to simplify and scale subscription bundling

Bango PLC Bango enables seamless migration from in-house platform, accelerating partner onboarding and expanding subscription choice for customers CAMBRIDGE, United Kingdom, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Bango (AIM: BGO), the leader in subscription bundling, today announced a partnership with Proximus, the largest telco …

Maximus, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:MMS) 2026-08-06

Optimum Communications, Inc. (OPTU) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

[10-Q] Optimum Communications, Inc. Quarterly Earnings Report

Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm

If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648. Click here to participate in the action. …

Maximus earnings on deck amid AI push and revenue headwinds

Maximus Inc. is set to report its fiscal third-quarter results, with analysts expecting $2.18 EPS on $1.33 billion revenue. Investors will focus on the company's ability to sustain margin gains from AI investments like Accuracy Assistant amidst revenue headwinds and a projected 1.5% decline …

Simulations Plus Chief Revenue Officer John Anthony DiBella II sells 1,000 shares for $18,280

Simulations Plus Chief Revenue Officer John Anthony DiBella II sold 1,000 common shares on August 3rd for $18.28 each, totaling $18,280. This transaction reduced his direct holdings to 85,140 shares. The information was generated using AI from a filing with the U.S. Securities and …

Biotech Stocks At 52-Week Highs - UFPT +25%, INFU +33%, SOPH +20% On Q2 Reports, REPL, PBLS

(RTTNews) - The following biotech stocks reached a 52-week high on August 4, 2026, driven by key catalysts like positive quarterly results or certain regulatory milestones. UFP Technologies Inc. (UFPT) UFP Technologies is a contract development and manufacturing organization specializing in solutions for medical …

Altice USA Ord Shs Class A (OPTU) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Altice USA Ord Shs Class A (OPTU), including analyst ratings and future EPS and revenue growth estimates. Based on 14 analysts, the stock has a "Hold" rating with a target price indicating a 46.05% upside. The expected …

Maximus Earnings: What To Look For From MMS

Maximus (MMS) is set to report its earnings this Thursday morning. The government services provider missed revenue expectations last quarter but beat EPS estimates. Analysts anticipate a 1.6% year-on-year revenue decline for the upcoming quarter, and the stock has seen positive sentiment, with its …

Imunon, Inc. (IMNN) general counsel grants and sells 2,541 shares

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, received 2,541 shares of common stock on July 31, 2026, as part of her base salary, valued at $1.59 per share. She subsequently sold all 2,541 shares on August 3, 2026, at a weighted average …

REPL SHAREHOLDER ALERT: Replimune Group Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

Kirby McInerney LLP is investigating Replimune Group Inc. (NASDAQ: REPL) following a significant drop in its stock price. The decline occurred after the FDA deemed Replimune's mid-stage study for its skin cancer drug "non interpretable," raising concerns about potential federal securities law violations. Investors …

Imunon (NASDAQ: IMNN) awards director 6,180 shares for board fees

Imunon, Inc. (NASDAQ: IMNN) director Donald P. Braun was granted 6,180 shares of common stock on July 31, 2026, valued at $1.59 per share. These shares were issued in lieu of cash for a portion of his board fees. Following this transaction, Braun directly …

Imunon (IMNN) director granted 6,934 shares of stock for board fees

Imunon, Inc. director James E. Dentzer was granted 6,934 shares of common stock on July 31, 2026, as compensation for a portion of his board fees. The stock grant was valued at $1.59 per share, bringing his total direct holdings to 21,897 shares. This …

Simulations Plus, Inc. (SLP) CRO sells 1,000 shares under Rule 10b5-1 plan

Simulations Plus, Inc.'s Chief Revenue Officer, John Anthony DiBella II, sold 1,000 shares of common stock on August 3, 2026, at $18.28 per share through a Rule 10b5-1 trading plan. Following this transaction, DiBella directly holds 85,140 shares. The sale was executed automatically and …

Replimune Group : REPL

This article provides an overview of Replimune Group Inc. (REPL), a biotechnology firm specializing in oncolytic immunotherapies for cancer treatment. It

Leerink Partners Upgrades Replimune Group to Outperform From Market Perform, Adjusts Price Target to $17 From $11

Leerink Partners has upgraded Replimune Group to "Outperform" from "Market Perform" and raised its price target to $17 from $11. This upgrade follows a series of positive developments for Replimune, including favorable outcomes from an FDA Advisory Committee meeting for its lead product candidate, …

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026

IMUNON, Inc. will host a conference call on Tuesday, August 11, 2026, at 11:00 a.m. EDT to discuss its second quarter 2026 financial results. The call will also provide an update on its clinical development program, including progress for IMNN-001 in advanced ovarian cancer. …

Class Action Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of September 22, 2025 Deadline

Levi & Korsinsky reminds investors of Replimune Group, Inc. (REPL) about a class action lawsuit with a September 22, 2025 deadline. The lawsuit alleges that Replimune Group, Inc. made false and misleading statements about the IGNYTE trial, which the FDA deemed inadequate. Investors who …

Simulations Plus (NASDAQ:SLP) Stock Price Passes Above 200-Day Moving Average - Here's Why

Simulations Plus (SLP) insider schedules 3,000-share Rule 144 sale and details 10b5-1 trades

Simulations Plus (SLP) insider John Anthony DiBella II has filed a Rule 144 notice to sell 3,000 common shares, valued at $54,690, which originated from previously exercised options. The filing also details three separate 10b5-1 plan sales, each for 1,000 shares, that occurred in …

Imunon Inc expected to post a loss of 93 cents a share - Earnings Preview

Imunon Inc is anticipated to report a loss of 93 cents per share, according to an earnings preview. This financial outlook provides investors with an expectation for the company's upcoming earnings report. The full article is available through TradingView, which offers access to Reuters …

Why Replimune Group (REPL) Is Up 15.5% After Key FDA Panel Backing For RP1 Data - And What's Next

Replimune Group's stock (REPL) rose 15.5% after an FDA advisory committee voted 10–3 that the efficacy data from its IGNYTE trial for RP1 in advanced melanoma are evaluable and clinically meaningful, ahead of an August 2, 2026 action date. The article highlights the importance …

Replimune Group, Inc. Actuals & Estimates (NASDAQ:REPL)

This article provides an overview of Replimune Group, Inc. (NASDAQ:REPL) financial actuals, estimates, and stock performance. It covers current stock price, historical highs and lows, market capitalization, earnings reports, and analyst forecasts. The article also addresses frequently asked questions about investing in REPL stock …

This Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatment

Replimune Group's stock surged by 107% after an FDA panel voted 10-3 in favor of its experimental skin cancer treatment. This positive vote indicates a significant step forward for the biotechnology company's new therapy.

Maximus (MMS) Earnings Date and Reports 2026

Maximus (MMS) issued its Q2 2026 earnings on May 7, 2026, reporting an EPS of $2.07, surpassing analysts' estimates, although quarterly revenue of $1.31 billion was slightly below expectations. The company's earnings are projected to grow by 5.10% next year. Maximus's Q3 2026 earnings …

Proximus SA (BGAOF) (Q2 2026) Earnings Call Highlights: Fiber Expansion and Strategic ...

This article first appeared on GuruFocus. Domestic Revenue: Increased by 1.1% in Q2 2026, supported by higher IT hardware and terminals revenue. Residential Revenue: Increased by 2.2% year-on-year, driven by a 2.1% rise in customer services revenue. Convergent Revenue: Grew by 3.9% in the …

Top Midday Gainers

Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.The committee voted 10 to 3 that the efficacy Silver Upgrade …

Replimune rebounds as positive AdCom vote prompts Cantor upgrade

[Wall Street New York stock exchange stock market] alexsl Despite a multi-day decline earlier this week, Replimune (REPL [https://seekingalpha.com/symbol/REPL]) shares bounced back on Friday as Cantor Fitzgerald upgraded the biotech after an FDA advisory committee voted in favor of the company’s lead, RP1, targeted …

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote

Replimune Group's shares more than doubled after a positive FDA advisory committee vote on its IGNYTE study data for RP1 in combination with nivolumab for advanced melanoma. The committee voted 10 to 3 that the study results are clinically meaningful and evaluable, despite previous …

FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote

An FDA advisory panel voted 10-3 in favor of Replimune's experimental melanoma treatment, RP1, increasing its chances of approval despite two prior rejections and concerns from FDA scientists about the trial data. The decision comes ahead of an August 2 deadline for the FDA …